The AUGMENT study: Lenalidomide in indolent lymphoma … balance the imbalance!

Abstract

Follicular lymphoma is the most common form of indolent Non-Hodgkin Lymphoma and characterized by repeated relapses. Follicular lymphoma (FL) tissue was found to have association between malignant cells and benign immune cells represented in the surrounded microenvironment. Lenalidomide, an immunomodulator, is affecting this microenvironment and demonstrated relevant clinical activity in phase III trials in patients with FL lymphoma. The AUGMENT trial resulted in a better PFS with lenalidomide and rituximab than rituximab and placebo in patients with relapsed/refractory FL and marginal zone lymphoma. However, there are some concerns around the study. The following article is discussing some of these concerns.

• Authors: Reyad Dada
• Journal: Hematology/oncology and stem cell therapy (Hematol Oncol Stem Cell Ther) Vol. 13 Issue 1 Pg. 46-47 (Mar 2020) ISSN: 2589-0646 [Electronic] Saudi Arabia
• PMID: 31676307 (Publication Type: Letter)
• Copyright: Copyright © 2019 King Faisal Specialist Hospital & Research Centre. Published by Elsevier Ltd. All rights reserved.

Chemical References

• Angiogenesis Inhibitors
• Lenalidomide

Topics

• Angiogenesis Inhibitors (pharmacology, therapeutic use)
• Female
• Humans
• Lenalidomide (pharmacology, therapeutic use)
• Lymphoma, Non-Hodgkin (drug therapy, pathology)
• Male